| Literature DB >> 32914327 |
Martina Budel1, Luca Martella2, Laura Zambon1, Isabella Morson1, Giorgio Giorda2, Renato Cannizzaro3,4.
Abstract
The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.Entities:
Keywords: Gynecological cancers; Lanreotide; Percutaneous endoscopic gastrostomy
Year: 2020 PMID: 32914327 PMCID: PMC7767898 DOI: 10.1007/s00520-020-05745-x
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603